European Commission secures 300 million additional doses of BioNTech-Pfizer vaccine

The European Commission has proposed to the 27 EU Member States to purchase up to 300 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer. This would mean that the EU is able to purchase up to 600 million doses of this vaccine, which is already being used across the EU. The additional doses will be delivered to Member States at the start of the second quarter of 2021.

In addition to this, the EU has acquired a broad portfolio of vaccines with different technologies. The EU has secured up to 2.3 billion doses from the most promising vaccine candidates for Europe and its neighbourhood.  Further to the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on 6 January 2021. Other vaccines are expected to be approved soon.

The purchase of such vaccines enables the EU not only to cover the needs of its whole population, but also to supply vaccines to neighbouring countries.

More information about Safe COVID-19 vaccines for Europeans can be accessed here.

« Back